Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. European Centre for Disease Prevention and Control. Communicable disease threats report, 22–28 June 2024, week 26. 28. Jun 2024. https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-22-28-june-2024-week-26 (accessed July 7, 2024).
2. Centers for Disease Control and Prevention. United States covid-19 deaths, emergency department (ED) visits, and test positivity by geographic area. 1 Jul 2024. https://covid.cdc.gov/covid-data-tracker/#maps_percent-covid-deaths (accessed July 7, 2024).
3. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–45.
4. Wu TY, Tsai WT, Chen KH, et al. Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies. J Microbiol Immunol Infect. 2024;57(3):403–13. https://doi.org/10.1016/j.jmii.2024.03.001.
5. Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–16.